Overview of Dr. Gregory
Tara Gregory, MD, is a board-certified, fellowship-trained medical oncologist with a focus on plasma cell diseases such as multiple myeloma, amyloidosis, monoclonal gammopathies and plasma cell leukemia. Fluent in both English and Spanish, Dr. Gregory is passionate about educating patients to ensure they understand their disease and working in partnership with patients to make treatment decisions that honor quality of life as well as outcomes.
Dr. Gregory earned her Bachelor of Arts summa cum laude in Hispanic Linguistics and her honors thesis focused on the critical age of learning and brain plasticity. She also received her Bachelor of Science in molecular and cellular biology summa cum laude and wrote her honors thesis on the expression of iNOS in mouse cardiac transplant grafts. She then graduated from the University of Arizona School of Medicine in Tucson, AZ and did a residency in internal medicine at the Banner Good Samaritan/Carl T. Hayden VAMC program. Dr. Gregory then moved to Denver, CO to complete her medical oncology fellowship at the University of Colorado. After finishing the fellowship, Dr. Gregory was the first blood and marrow transplant fellow at CBCI. Today, Dr. Gregory is the co-director of the Plasma Cell Dyscrasia Program at CBCI focusing on diseases such as multiple myeloma, amyloidosis, monoclonal gammopathies and plasma cell leukemia. The focus of her research work is in multiple myeloma treatments including chimeric antigen T cell therapy.
Dr. Gregory is a member of several societies, including the International Myeloma Society, American Society of Hematology, the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation. She actively participates in clinical trials including research in blood and marrow transplant outcomes, the results which have been presented at multiple research meetings.
Office
1721 E 19th Ave
Ste 300
Denver, CO 80218Fax+1 720-754-4801
Education & Training
- University of ColoradoFellowship, Hematology and Medical Oncology, 2007 - 2009
- University of Arizona College of Medicine-PhoenixResidency, Internal Medicine, 2004 - 2007
- University of Arizona College of MedicineClass of 2004
Certifications & Licensure
- CO State Medical License 2008 - 2025
- NM State Medical License 2013 - 2022
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease Start of enrollment: 2010 Aug 01
- Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
- Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression Start of enrollment: 2010 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsChimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.Paolo Strati, Tara Gregory, Navneet S Majhail, Nitin Jain
JCO Oncology Practice. 2023-09-01 - 83 citationsTumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Scott C. Howard, Steven Trifilio, Tara K. Gregory, Nadine Baxter, Ali McBride
Annals of Hematology. 2016-01-12 - 3 citationsAllogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.Fateeha Furqan, Kwang W Ahn, Yue Chen, Manmeet Kaur, Syed A Abutalib
British Journal of Haematology. 2023-01-01
Abstracts/Posters
- A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...Tara K. Gregory, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...Tara K. Gregory, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant AbstractTara K. Gregory, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
- CAR T-cell Therapies Targeting CD20 Show Early Potential to Prevent, Mitigate NHL RelapseJune 8th, 2021
- Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem KeyCare PPO
Anthem PPO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPOFirst Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Rocky Mountain Group/Indiv - HMO/Private Pay
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: